Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

Abstract: An assay is provided for detecting and characterizing chromosomal rearrangements in eukaryotic cells by genetically engineering a eukaryotic cell to contain a selectable/counter-selectable marker gene with a site for generating a double strand break within an intron of the eukaryotic cell; generating the double strand break; detecting cells which repair the double strand break by chromosomal rearrangements; isolating DNA from the detected cells; and characterizing the chromosomal rearrangement as a nonhomologous translocation, inversion, deletion or insertion.

Abstract: The present invention provides cDNAs encoding deoxyribonuclease II and isolated, purified deoxyribonuclease II proteins. Antibodies against this protein and antisense agents targeted to a cDNA or corresponding mRNA encoding deoxyribonuclease II are provided. In addition, methods of identifying and using modulators of deoxyribonuclease II activity and apoptosis are described.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of daxx. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding daxx. Methods of using these compounds for modulation of daxx expression and for treatment of diseases associated with expression of daxx are provided.

Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr;-converting enzyme (TACE). Antisense oligonucleotides targeted to nucleic acids encoding TACE are preferred. Methods of using these oligonucleotides for inhibition of TACE expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TACE or TNF-&agr; are provided.

Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Integrin-linked kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Integrin-linked kinase. Methods of using these compounds for modulation of Integrin-linked kinase expression and for treatment of diseases associated with expression of Integrin-linked kinase are provided.

Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

Abstract: Oligonucleotides and oligonucleotide analogs are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide or oligonucleotide analog is provided which is hybridizable with a messenger RNA from a papillomavirus. The oligonucleotide or oligonucleotide analog is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E1, E7, E6 or E6-7 messenger RNAs.

Abstract: A nucleic acid sequence encoding a variant CYP3A4 gene is provided. Also provided are methods and kits for identifying individuals carrying a variant CYP3A4 gene with a heightened risk of developing or having prostate cancer or a decreased risk for developing treatment-related leukemias and identifying more effective and safer treatment regimes for individuals based upon their CYP3A4 genotype.

Abstract: Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided.

Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of RANK. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RANK. Methods of using these compounds for inhibition of RANK expression and for treatment of diseases associated with expression of RANK are provided.

Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5′-untranslated sequences, 3′-untranslated sequences, and intervening sequences.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK1. Methods of using these compounds for modulation of MEKK1 expression and for treatment of diseases associated with expression of MEKK1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of Nucleolin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Nucleolin. Methods of using these compounds for modulation of Nucleolin expression and for treatment of diseases associated with expression of Nucleolin are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 3. Methods of using these compounds for modulation of E2F transcription factor 3 expression and for treatment of diseases associated with expression of E2F transcription factor 3 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hnRNP A1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hnRNP A1. Methods of using these compounds for modulation of hnRNP A1 expression and for treatment of diseases associated with expression of hnRNP A1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of PI3 kinase p55 gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p55 gamma. Methods of using these compounds for inhibition of PI3 kinase p55 gamma expression and for treatment of diseases associated with expression of PI3 kinase p55 gamma are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of nck-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding nck-2. Methods of using these compounds for modulation of nck-2 expression and for treatment of diseases associated with expression of nck-2 are provided.